WALTHAM, Mass., March 1, 2021 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, announced today that it
will release its fourth quarter and year-end 2020 financial results
on Monday, March 8, after the close
of the U.S. financial markets.
In connection with the earnings release, Syndax's management
team will host a conference call and live audio webcast at
4:30 p.m. ET on Monday, March 8, to
discuss the Company's financial results and provide a general
business update.
The live audio webcast and accompanying slides may be accessed
through the Events & Presentations page in the Investors
section of the Company's website at www.syndax.com. Alternatively,
the conference call may be accessed through the following:
Conference ID: 7949816
Domestic Dial-in Number: (855) 251-6663
International Dial-in Number: (281) 542-4259
Live webcast: https://edge.media-server.com/mmc/p/wdaqmgg3
For those unable to participate in the conference call or
webcast, a replay will be available on the Investors section of the
Company's website, www.syndax.com.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies. The
Company's pipeline includes SNDX-5613, a highly selective inhibitor
of the Menin–MLL binding interaction, axatilimab, a monoclonal
antibody that blocks the colony stimulating factor 1 (CSF-1)
receptor, and entinostat, a class I HDAC inhibitor. For more
information, please visit www.syndax.com or follow the
Company on Twitter and LinkedIn.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-to-announce-fourth-quarter-and-year-end-2020-financial-results-and-host-conference-call-and-webcast-on-march-8-2021-301236837.html
SOURCE Syndax Pharmaceuticals, Inc.